Table 2.
Disease characteristics and medications
| HTN (n, M/F) | HFpEF (n, M/F) | |
|---|---|---|
| Disease characteristics | ||
| NYHA class II | 7/7 | |
| NYHA class III | 2/7 | |
| NYHA class IV | 2/0 | |
| Diabetes | 0/0 | 4/4 |
| COPD | 0/0 | 2/0 |
| CAD | 1/1 | 2/4 |
| Hypertension | 15/10 | 7/11 |
| Hyperlipidemia | 3/1 | 5/7 |
| Medications | ||
| Beta-blockers | 2/0 | 3/9 |
| ACEi | 3/2 | 3/7 |
| ARB | 1/1 | 3/3 |
| Loop diuretics | 0/0 | 9/14 |
| Aldosterone antagonists | 1/1 | 7/12 |
| Statin | 1/1 | 5/11 |
| Nitrates | 0/1 | 2/3 |
| Ca2+ channel blocker | 0/1 | 1/2 |
| Rx types taken | 0.6 ± 0.9 | 3.8 ± 1.3 |
Values for Rx types taken are means ± SD. HTN, hypertension; HFpEF, heart failure with preserved ejection fraction; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; NYHA class, New York Heart Association functional classification; Rx, prescription.